Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial elongation factor 2—more accurately named Mitochondrial dynamics protein MID49 (MID49) and encoded by the MIEF2 gene in humans—is an outer mitochondrial membrane protein that plays a crucial regulatory role in mitochondrial fission. MID49 acts as a peripheral receptor for the cytosolic GTPase Drp1, recruiting it to the mitochondrial surface to facilitate mitochondrial division. Structural studies show that MID49 physically interacts with Drp1 through protein-protein contact rather than by co-factors, and this interaction is essential for mitochondrial morphology and cellular metabolism regulation. Deficiency or depletion of MID49 leads to reduced fission, altered mitochondrial length, disrupted metabolism, and increased oxidative stress. MID49 has multiple aliases and is a current focus of investigation as a potential therapeutic target in diseases involving defective mitochondrial dynamics
Promotes mitochondrial fission by recruiting and physically interacting with dynamin-related protein 1 (Drp1) to the mitochondrial surface, stimulating Drp1 GTPase activity and assembly to drive membrane scission
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial dynamics protein MID49 (MID49).